Treatment Paradigm Evolution and Systemic Therapy Selection for Patients with Desmoid Tumors

Dr. Basu Mallick describes the fundamental shift in treatment philosophy following availability of effective systemic therapies from phase 3 trials. She now has a lower threshold for initiating systemic therapy compared to local interventions, given better-understood efficacy profiles and toxicity management for systemic approaches.

Gamma-secretase inhibitors represent first-line choices due to FDA approval and insurance accessibility, though patient-specific factors influence selection. Hypertensive patients may not be suitable for sorafenib, whereas young women considering pregnancy require careful counseling about potential ovarian toxicity from gamma-secretase inhibitors, though effects appear largely reversible.

Dr. Bui addresses the paradigmatic shift away from surgery as first-line treatment. Historically high recurrence rates even after margin-negative resections, combined with potential surgical morbidity in complex anatomical locations, have moved the field toward non-surgical approaches. Large chest wall tumors may require rib removal, whereas abdominal wall lesions necessitate mesh placement with significant functional impact.

Current surgical indications are limited to emergency scenarios like intestinal perforation or obstruction, or to highly selected cases where procedures carry minimal morbidity and provide rapid symptomatic relief. The availability of effective active surveillance, improved local therapies like cryoablation, and proven systemic treatments has relegated surgery to exceptional circumstances.

Both panelists emphasize that radiation therapy use has declined significantly due to secondary malignancy risks in young patients with benign locally aggressive tumors. The median age of approximately 40 years means patients face decades of potential exposure to radiation-induced complications, making the risk-benefit ratio unfavorable when effective systemic alternatives exist.